论文部分内容阅读
目的探讨肿瘤异常蛋白(TAP)在非小细胞肺癌(NSCLC)中的临床价值。方法202例肺部结节患者,根据术后病理分成NSCLC组(102例)和肺良性病变组(100例),测定患者外周血中TAP的表达。结果 NSCLC组TAP阳性表达率为73.53%,高于肺良性病变组的10.00%(P<0.01)。在NSCLC组中,腺癌和鳞状细胞癌的TAP阳性表达率分别为72.73%和78.57%。在肺良性病变组中,炎性结节、结核结节和不典型增生的TAP阳性表达率分别为4.62%、10.00%和33.33%。结论 NSCLC患者血清TAP表达量明显高于肺良性病变者,检测TAP表达有助于肺部病变性质的鉴别判断。
Objective To investigate the clinical value of TAP in non-small cell lung cancer (NSCLC). Methods Totally 202 patients with pulmonary nodules were divided into NSCLC group (n = 102) and benign lung group (n = 100) according to postoperative pathology. TAP expression in peripheral blood was measured. Results The positive expression rate of TAP in NSCLC group was 73.53%, which was higher than that in benign lung group (10.00%, P <0.01). In the NSCLC group, the positive rates of TAP expression in adenocarcinoma and squamous cell carcinoma were 72.73% and 78.57%, respectively. In the group of benign lung disease, the positive rates of TAP in inflammatory nodules, tuberculodules and atypical hyperplasia were 4.62%, 10.00% and 33.33%, respectively. Conclusion The expression of TAP in serum of patients with NSCLC is significantly higher than that of patients with benign lung disease. Detecting the expression of TAP contributes to the differential diagnosis of pulmonary lesions.